Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Equity Issued and Repurchased Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Solid Biosciences (SLDB) Change in Receivables (2021 - 2022)

Solid Biosciences (SLDB) has disclosed Change in Receivables for 2 consecutive years, with -$14000.0 as the latest value for Q2 2022.

Quarterly Change in Receivables fell 333.33% to -$14000.0 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was -$110000.0 through Dec 2022, down 200.0% year-over-year, with the annual reading at -$110000.0 for FY2022, 200.0% down from the prior year.
Change in Receivables hit -$14000.0 in Q2 2022 for Solid Biosciences, up from -$96000.0 in the prior quarter.
In the past five years, Change in Receivables ranged from a high of $308000.0 in Q3 2021 to a low of -$484000.0 in Q4 2021.